Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$31.59
-1.6%
$28.36
$13.09
$35.66
$879.57M0.87400,278 shs206,786 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.50
+1.2%
$3.83
$2.83
$5.55
$209.06M1.25557,205 shs540,804 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
+3.75%+11.11%+8.08%+69.62%+112.79%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+4.22%-4.42%-16.63%-22.25%+2.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CryoPort, Inc. stock logo
CYRX
CryoPort
$14.62
+1.7%
$12.42
$6.16
$16.73
$724.78M1.9991,421 shs502,102 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$31.59
-1.6%
$28.36
$13.09
$35.66
$879.57M0.87400,278 shs206,786 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$8.88
+3.0%
$5.25
$1.50
$13.24
$711.78M0.916.86 million shs1.97 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.50
+1.2%
$3.83
$2.83
$5.55
$209.06M1.25557,205 shs540,804 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.64%-11.01%+10.28%+83.89%+108.10%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
+3.75%+11.11%+8.08%+69.62%+112.79%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+1.77%-12.66%+110.76%+20.73%-11.86%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+4.22%-4.42%-16.63%-22.25%+2.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CryoPort, Inc. stock logo
CYRX
CryoPort
2.80
Moderate Buy$15.113.36% Upside
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.40
Hold$41.0029.79% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
1.70
Reduce$4.88-45.10% Downside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
2.75
Moderate Buy$16.50371.43% Upside

Current Analyst Ratings Breakdown

Latest VYGR, ETON, CYRX, and REPL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Set Price Target$13.50
6/8/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Reiterated RatingHold$13.00
6/3/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
DowngradeSell (D-)Sell (E+)
6/3/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetBuy$15.00 ➝ $20.00
6/1/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Boost Price TargetNeutral$2.00 ➝ $6.00
5/29/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
UpgradeUnderweightNeutral$8.00
5/26/2026
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
Reiterated RatingBuy
5/20/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
Boost Price TargetOverweight$15.00 ➝ $17.00
5/15/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Boost Price TargetBuy$52.00 ➝ $57.00
5/8/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
UpgradeSell (E+)Sell (D-)
5/6/2026
CryoPort, Inc. stock logo
CYRX
CryoPort
UpgradeSell (D+)Hold (C-)
(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CryoPort, Inc. stock logo
CYRX
CryoPort
$176.18M4.18N/AN/A$9.19 per share1.59
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$79.95M10.82$0.01 per share6,195.02$0.98 per share32.23
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$40.37M5.24N/AN/A$3.53 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CryoPort, Inc. stock logo
CYRX
CryoPort
$78.30M$1.3510.83N/AN/A41.57%-7.92%-4.79%8/4/2026 (Estimated)
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$4.60M-$0.07N/A16.54N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/12/2026 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)

Latest VYGR, ETON, CYRX, and REPL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/12/2026Q4 2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.73N/AN/AN/A$5.57 millionN/A
5/14/2026Q1 2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.10$0.05-$0.05$0.05$22.31 million$24.27 million
5/7/2026Q1 2026
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million
5/4/2026Q1 2026
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20-$0.23-$0.03-$0.25$44.86 million$47.80 million
3/19/2026Q4 2025
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.12$0.05-$0.07$0.05$20.58 million$21.28 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CryoPort, Inc. stock logo
CYRX
CryoPort
N/A
2.09
2.00
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.62
1.21
0.88
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.33
5.60
5.60
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
8.42
8.42

Institutional Ownership

CompanyInstitutional Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
16.49%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.20%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
12.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.40 million45.36 millionOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2027.39 million22.88 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21082.57 million78.28 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10060.42 million52.75 millionOptionable

Recent News About These Companies

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

New MarketBeat Followers Over Time

Media Sentiment Over Time

CryoPort stock logo

CryoPort NASDAQ:CYRX

$14.62 +0.24 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$14.79 +0.17 (+1.16%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Eton Pharmaceuticals stock logo

Eton Pharmaceuticals NASDAQ:ETON

$31.59 -0.52 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$31.57 -0.02 (-0.06%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$8.88 +0.26 (+3.02%)
Closing price 04:00 PM Eastern
Extended Trading
$8.85 -0.04 (-0.39%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.50 +0.04 (+1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 +0.02 (+0.43%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.